Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SygeLIX-F and SygeLIX-G for Resistant Anal Fistulas
NCT05638139Phase 1Completed
- Sponsor
- TBF Génie Tissulaire
- Start
- Jun 2023
- Primary completion
- Jun 2024
- Modality
- Small Molecules, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of myo-inositol + folic acid and SygeLIX-G in anal fistula, sponsored by TBF Génie Tissulaire. Primary endpoints: Evaluation of intensity of perineal inflammation following treatment at 45 days, Rate of plug expulsion and surgical revision due to complications at 45 days and 1 more. Started Jun 2023; status: completed.
02
Drugs
myo-inositol + folic acidSygeLIX-G
03
Conditions
anal fistula
Beyond the preview
Go deeper on NCT05638139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05638139.